Cargando…

The impact of patient co-morbidities on the regenerative capacity of cardiac explant-derived stem cells

BACKGROUND: Although patient-sourced cardiac stem cells repair damaged myocardium, the extent to which medical co-morbidities influence cardiac-derived cell products is uncertain. Therefore, we investigated the influence of atherosclerotic risk factors on the regenerative performance of human cardia...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayfield, Audrey E., Fitzpatrick, Megan E., Latham, Nicholas, Tilokee, Everad L., Villanueva, Melanie, Mount, Seth, Lam, Bu-Khanh, Ruel, Marc, Stewart, Duncan J., Davis, Darryl R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880978/
https://www.ncbi.nlm.nih.gov/pubmed/27225482
http://dx.doi.org/10.1186/s13287-016-0321-4
_version_ 1782433885743742976
author Mayfield, Audrey E.
Fitzpatrick, Megan E.
Latham, Nicholas
Tilokee, Everad L.
Villanueva, Melanie
Mount, Seth
Lam, Bu-Khanh
Ruel, Marc
Stewart, Duncan J.
Davis, Darryl R.
author_facet Mayfield, Audrey E.
Fitzpatrick, Megan E.
Latham, Nicholas
Tilokee, Everad L.
Villanueva, Melanie
Mount, Seth
Lam, Bu-Khanh
Ruel, Marc
Stewart, Duncan J.
Davis, Darryl R.
author_sort Mayfield, Audrey E.
collection PubMed
description BACKGROUND: Although patient-sourced cardiac stem cells repair damaged myocardium, the extent to which medical co-morbidities influence cardiac-derived cell products is uncertain. Therefore, we investigated the influence of atherosclerotic risk factors on the regenerative performance of human cardiac explant-derived cells (EDCs). METHODS: In this study, the Long Term Stratification for survivors of acute coronary syndromes model was used to quantify the burden of cardiovascular risk factors within a group of patients with established atherosclerosis. EDCs were cultured from human atrial appendages and injected into immunodeficient mice 7 days post-left coronary ligation. Cytokine arrays and enzyme linked immunoassays were used to determine the release of cytokines by EDCs in vitro, and echocardiography was used to determine regenerative capabilities in vivo. RESULTS: EDCs sourced from patients with more cardiovascular risk factors demonstrated a negative correlation with production of pro-healing cytokines (such as stromal cell derived factor 1α) and exosomes which had negative effects on the promotion of angiogenesis and chemotaxis. Reductions in exosomes and pro-healing cytokines with accumulating medical co-morbidities were associated with increases in production of the pro-inflammatory cytokine interleukin-6 (IL-6) by EDCs. Increased patient co-morbidities were also correlated with significant attenuation in improvements of left ventricular ejection fraction. CONCLUSIONS: The regenerative performance of the earliest precursor cell population cultured from human explant tissue declines with accumulating medical co-morbidities. This effect is associated with diminished production of pro-cardiogenic cytokines and exosomes while IL-6 is markedly increased. Predictors of cardiac events demonstrated a lower capacity to support angiogenesis and repair injured myocardium in a mouse model of myocardial infarction. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13287-016-0321-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4880978
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48809782016-05-27 The impact of patient co-morbidities on the regenerative capacity of cardiac explant-derived stem cells Mayfield, Audrey E. Fitzpatrick, Megan E. Latham, Nicholas Tilokee, Everad L. Villanueva, Melanie Mount, Seth Lam, Bu-Khanh Ruel, Marc Stewart, Duncan J. Davis, Darryl R. Stem Cell Res Ther Research BACKGROUND: Although patient-sourced cardiac stem cells repair damaged myocardium, the extent to which medical co-morbidities influence cardiac-derived cell products is uncertain. Therefore, we investigated the influence of atherosclerotic risk factors on the regenerative performance of human cardiac explant-derived cells (EDCs). METHODS: In this study, the Long Term Stratification for survivors of acute coronary syndromes model was used to quantify the burden of cardiovascular risk factors within a group of patients with established atherosclerosis. EDCs were cultured from human atrial appendages and injected into immunodeficient mice 7 days post-left coronary ligation. Cytokine arrays and enzyme linked immunoassays were used to determine the release of cytokines by EDCs in vitro, and echocardiography was used to determine regenerative capabilities in vivo. RESULTS: EDCs sourced from patients with more cardiovascular risk factors demonstrated a negative correlation with production of pro-healing cytokines (such as stromal cell derived factor 1α) and exosomes which had negative effects on the promotion of angiogenesis and chemotaxis. Reductions in exosomes and pro-healing cytokines with accumulating medical co-morbidities were associated with increases in production of the pro-inflammatory cytokine interleukin-6 (IL-6) by EDCs. Increased patient co-morbidities were also correlated with significant attenuation in improvements of left ventricular ejection fraction. CONCLUSIONS: The regenerative performance of the earliest precursor cell population cultured from human explant tissue declines with accumulating medical co-morbidities. This effect is associated with diminished production of pro-cardiogenic cytokines and exosomes while IL-6 is markedly increased. Predictors of cardiac events demonstrated a lower capacity to support angiogenesis and repair injured myocardium in a mouse model of myocardial infarction. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13287-016-0321-4) contains supplementary material, which is available to authorized users. BioMed Central 2016-05-26 /pmc/articles/PMC4880978/ /pubmed/27225482 http://dx.doi.org/10.1186/s13287-016-0321-4 Text en © Mayfield et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Mayfield, Audrey E.
Fitzpatrick, Megan E.
Latham, Nicholas
Tilokee, Everad L.
Villanueva, Melanie
Mount, Seth
Lam, Bu-Khanh
Ruel, Marc
Stewart, Duncan J.
Davis, Darryl R.
The impact of patient co-morbidities on the regenerative capacity of cardiac explant-derived stem cells
title The impact of patient co-morbidities on the regenerative capacity of cardiac explant-derived stem cells
title_full The impact of patient co-morbidities on the regenerative capacity of cardiac explant-derived stem cells
title_fullStr The impact of patient co-morbidities on the regenerative capacity of cardiac explant-derived stem cells
title_full_unstemmed The impact of patient co-morbidities on the regenerative capacity of cardiac explant-derived stem cells
title_short The impact of patient co-morbidities on the regenerative capacity of cardiac explant-derived stem cells
title_sort impact of patient co-morbidities on the regenerative capacity of cardiac explant-derived stem cells
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880978/
https://www.ncbi.nlm.nih.gov/pubmed/27225482
http://dx.doi.org/10.1186/s13287-016-0321-4
work_keys_str_mv AT mayfieldaudreye theimpactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells
AT fitzpatrickmegane theimpactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells
AT lathamnicholas theimpactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells
AT tilokeeeveradl theimpactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells
AT villanuevamelanie theimpactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells
AT mountseth theimpactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells
AT lambukhanh theimpactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells
AT ruelmarc theimpactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells
AT stewartduncanj theimpactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells
AT davisdarrylr theimpactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells
AT mayfieldaudreye impactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells
AT fitzpatrickmegane impactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells
AT lathamnicholas impactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells
AT tilokeeeveradl impactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells
AT villanuevamelanie impactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells
AT mountseth impactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells
AT lambukhanh impactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells
AT ruelmarc impactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells
AT stewartduncanj impactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells
AT davisdarrylr impactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells